VAXXITEK® HVT+ IBD | BCH-LMO-SCBD-109735 | Living Modified Organism | Biosafety Clearing-House

Loading...
  |  

Living Modified Organism (LMO)

Decisions on the LMO Risk Assessments  
last updated: 25 Feb 2016
Living Modified Organism identity
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.
VAXXITEK® HVT+ IBD
EN
vHTV013-69
  • - Person: Dra Luciana Fernanda Matias Soares | BCH-CON-SCBD-109734-2
    Person
    Dra Luciana Fernanda Matias Soares
    President of Internal Biosafety Commission, Animal Health
    Fazenda São Francisco s/nº - Caixa Postal: 242 - PAULINIA (SP)
    Paulínia, São Paulo
    13140970, Brazil
    Phone: +55 19 3874-8601,
    Fax: +55 19 3874-8080,
    Related Organization
    Merial Saúde Animal Ltda (Merial)
    Private sector (business and industry)
    Fazenda São Francisco s/nº - Caixa Postal: 242 - PAULINIA (SP)
    Paulínia, São Paulo
    13140970, Brazil
    Phone: +55 19 3874-8601,
    Fax: +55 19 3874-8080,
Vaxxitek HVT + IBD is a live vaccine based on the use of a recombinant turkey Herpesvirus (HVT) expressing the VP2 gene of the Infectious Bursal Disease (Gumboro disease) Virus (IBDV).

This vaccine contains a live strain of serotype 3 vectored virus that has been shown to aid in the prevention of Bursal disease and Marek's disease.
EN
The term “Recipient organism” refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas “Parental organisms” refers to those that were involved in cross breeding or cell fusion.
Meleagrid herpesvirus 1 (HVT) strain: FC-126
EN
  • VECTORMUNE® HVT-IBD
    | Dr Alexis Henry Gaetan Goux Production of medical or pharmaceutical compounds (human or animal) - Vaccines
Characteristics of the modification process
vHVT013-69
EN
  • Other (Homologous Recombination)
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
  • BCH-GENE-SCBD-105223-1 Viral Protein 2 gene | (Gumboro virus)
    Protein coding sequence | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
Vaxxitek HVT + IBD vaccine is a live recombinant vaccine against Gumboro disease (or infectious bursal disease) and Marek’s disease in chickens. It is a frozen vaccine to be diluted with an aqueous diluent. The active ingredient is the production-cell associated vHVT013-69 virus vaccine strain, a recombinant turkey Herpesvirus (HVT) expressing the VP2 coding sequence of Infectious Bursal Disease Virus (IBDV). The parental strain of Vaxxitek HVT + IBD (named FC-126) belongs to the serotype 3 of Marek's disease and is widely used in classical vaccination against Marek's disease. HVT strains are apathogenic in all species, and do not replicate in mammalian cells. The inserted sequence corresponds to the sequence coding for the VP2 protein of Infectious Bursal Disease Virus (IBDV). It has been cloned from 52/70 Faragher strain. The VP2 protein is the only protein of IBDV that induces protection against Gumboro disease.
EN
LMO characteristics
EN
  • Vaccine
Detection method(s)
EN
Additional Information
Records referencing this document Show in search
Record type Field Record(s)
Risk Assessment generated by a regulatory process Living modified organism(s) 2
Country's Decision or any other Communication Living modified organism(s) 1